Abstract:Objectives: To develop and validate predictive models for esophageal squamous cell carcinoma (ESCC) using circulating cell-free DNA (cfDNA) terminal motif analysis. The goal was to improve the non-invasive detection of early-stage ESCC and its precancerous lesions. Methods: Between August 2021 and November 2022, we prospectively collected plasma samples from 448 individuals at the Department of Endoscopy, Cancer Hospital, Chinese Academy of Medical Sciences for cfDNA extraction, library construction, and sequencing. We analyzed 201 cases of ESCC, 46 high-grade intraepithelial neoplasia (HGIN), 46 low-grade intraepithelial neoplasia (LGIN), 176 benign esophageal lesions, and 29 healthy controls. Participants, including ESCC patients and control subjects, were randomly assigned to a training set (n=284) and a validation set (n=122). The training cohort underwent z-score normalization of cfDNA terminal motif matrices and a selection of distinctive features differentiated ESCC cases from controls. The random forest classifier, Motif-1 (M1), was then developed through principal component analysis, ten-fold cross-validation, and recursive feature elimination. M1's efficacy was then validated in the validation and precancerous lesion sets. Subsequently, individuals with precancerous lesions were included in the dataset and participants were randomly allocated to newly formed training (n=243), validation (n=105), and test (n=150) cohorts. Using the same procedure as M1, we trained the Motif-2 (M2) random forest model with the training cohort. The M2 model's accuracy was then confirmed in the validation cohort to establish the optimal threshold and further tested by performing validation in the test cohort. Results: We developed two cfDNA terminal motif-based predictive models for ESCC and associated precancerous conditions. The first model, M1, achieved a sensitivity of 90.0%, a specificity of 77.4%, and an area under the curve (AUC) of 0.884 in the validation cohort. For LGIN, HGIN, and T1aN0 stage ESCC, M1's sensitivities were 76.1%, 80.4%, and 91.2% respectively. Notably, the sensitivity for jointly predicting HGIN and T1aN0 ESCC reached 85.0%. Both the predictive accuracy and sensitivity increased in line with the cancer's progression (P＜0.001). The second model, M2, exhibited a sensitivity of 87.5%, a specificity of 77.4%, and an AUC of 0.857 in the test cohort. M2's sensitivities for detecting precancerous lesions and ESCC were 80.0% and 89.7%, respectively, and it showed a combined sensitivity of 89.4% for HGIN and T1aN0 stage ESCC. Conclusions: Two predictive models based on cfDNA terminal motif analysis for ESCC and its precancerous lesions are developed. They both show high sensitivity and specificity in identifying ESCC and its precancerous stages, indicating its potential for early ESCC detection.

Application of Multicolor Fluorescence in Situ Hybridization to Early Diagnosis of Esophageal Squamous Cell Carcinoma

Aneuploid Analysis of Chromosomes 3, 8, 10, 20 and Y in Esophageal Squamous Cell Carcinoma

Identification of chromosome aberrations in esophageal cancer cell line KYSE180 by multicolor fluorescence in situ hybridization.

Identification of complex chromosome abnormalities in esophageal carcinoma cells KYSE450 by multicolor fluorescence in situ hybridization

Chromosome aberration of urine exfoliated cells to diagnose bladder neoplasm by fluorescence in situ hybridization

Chromosomal Aneuploidies and Combinational Fluorescence in Situ Hybridization Probe Panels Are Useful for Predicting Prognosis for Esophageal Squamous Cell Carcinoma

Characterization of Genetic Rearrangements in Esophageal Squamous Carcinoma Cell Lines by a Combination of M-FISH and Array-Cgh: Further Confirmation of Some Split Genomic Regions in Primary Tumors

Research of multicolor fluorescence in situ hybridization in the early diagnosis of colorectal cancer

Prevalence of Gene Amplifications of Sox-2, C-Met, and Fgfr1 in Asian Patients with Esophageal Squamous Cell Carcinoma.

[Development and Validation of Predictive Models for Esophageal Squamous Cell Carcinoma and Its Precancerous Lesions Using Terminal Motif Analysis in Circulating Cell-Free DNA].

Clinical Application of Multicolor Fluorescence in Situ Hybridization on Early Diagnosis of Lung Cancer

Artificial Intelligence Assisted Cytological Detection for Early Esophageal Squamous Epithelial Lesions by Using Low‐grade Squamous Intraepithelial Lesion As Diagnostic Threshold

Tissue Microarray Analysis Reveals a Tight Correlation Between Protein Expression Pattern and Progression of Esophageal Squamous Cell Carcinoma

AI-assisted Identification of Intrapapillary Capillary Loops in Magnification Endoscopy for Diagnosing Early-Stage Esophageal Squamous Cell Carcinoma: a Preliminary Study

[Expression of Fascin and Cytokeratin 14 in Esophageal Squamous Cell Carcinoma].

Early Diagnostic Markers for Esophageal Squamous Cell Carcinoma: CNA Gene Identification and cfDNA Detection

Chromosomes 5, 7 and 8 abnormalities in myelodysplastic syndromes by using interphase fluorescence in situ hybridization

Molecular analysis in combination with iodine staining may contribute to the risk prediction of esophageal squamous cell carcinoma

Quantitative Multiphoton Imaging of Cell Metabolism, Stromal Fibers, and Keratinization Enables Label-Free Discrimination of Esophageal Squamous Cell Carcinoma

Feasibility of using P16 methylation as a cytologic marker for esophageal squamous cell carcinoma screening: A pilot study

Detection of Chromosomes 5 and 7 Aberrations in Myelodysplastic Syndromes Using Dual-Color Fluorescence in Situ Hybridization